Kiora Pharmaceuticals (KPRX) Income from Continuing Operations (2016 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Income from Continuing Operations came in at 2417984.0 in Q1 2026, down 10.26% YoY from 2694438.63 in Q1 2025, and up 62.79% on a QoQ basis from 6498670.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 11 years of Income from Continuing Operations data on file, last reported at 2417984.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 10.26% year-over-year to 2417984.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11042307.0 (up 8.37% YoY) and the FY2025 annual result came in at 10817303.0, down 400.92% from the prior year.
- Income from Continuing Operations grew to 2417984.0 in Q1 2026, from 6498670.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 13453207.0 in Q1 2024 to a low of 35144478.0 in Q4 2023.
- A 5-year average of 3992792.65 and a median of 2577366.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 5550.65% — and 2024, when it jumped 801.62%.
- Tracing KPRX's Income from Continuing Operations over 5 years: stood at 2520348.0 in 2022, then slumped by 1294.43% to 35144478.0 in 2023, then soared by 87.98% to 4223502.0 in 2024, then sank by 53.87% to 6498670.0 in 2025, then soared by 62.79% to 2417984.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2417984.0 (Q1 2026), 6498670.0 (Q4 2025), and 26806.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | -2.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.08 Mn |
| Mar 31, 2026 | -2.42 Mn |
| Dec 31, 2025 | -6.50 Mn |
| Sep 30, 2025 | 26,806.00 |
| Jun 30, 2025 | -2.15 Mn |
| Mar 31, 2025 | -2.19 Mn |
| Dec 31, 2024 | -4.22 Mn |
| Sep 30, 2024 | -3.41 Mn |
| Jun 30, 2024 | -2.22 Mn |
| Mar 31, 2024 | 13.45 Mn |
| Dec 31, 2023 | -35.14 Mn |
| Sep 30, 2023 | -5.94 Mn |
| Jun 30, 2023 | -2.67 Mn |
| Mar 31, 2023 | -1.92 Mn |
| Dec 31, 2022 | -2.52 Mn |
| Sep 30, 2022 | -3.84 Mn |
| Jun 30, 2022 | -2.58 Mn |
| Mar 31, 2022 | -3.63 Mn |
| Dec 31, 2021 | -14.39 Mn |
| Sep 30, 2021 | -68,006.00 |